- Home
- VOR vs OBIO Comparison
VOR vs OBIO Comparison
Compare VOR & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | OBIO |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 237.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VOR | OBIO |
|---|---|---|
| Price | $15.70 | $4.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $64.78 | $14.25 |
| AVG Volume (30 Days) | ★ 1.1M | 217.8K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,818,000.00 |
| Revenue This Year | N/A | $35.75 |
| Revenue Next Year | N/A | $3.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $2.62 | $2.20 |
| 52 Week High | $65.80 | $6.16 |
Technical Indicators
Market Signals| Indicator | VOR | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 45.38 |
| Support Level | $13.00 | $4.06 |
| Resistance Level | $14.64 | $4.53 |
| Average True Range (ATR) | 1.45 | 0.30 |
| MACD | 0.30 | -0.03 |
| Stochastic Oscillator | 97.28 | 24.88 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.